Glembatumumab vedotin as a treatment in Triple Negative Breast Cancer
Tuesday, December 29, 2015
Linda Vahdat, M.D., professor of medicine, director of the Breast Cancer Research Program and chief of the Solid Tumor Service, spoke to Targeted Oncology about the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB. Vahdat says the purpose of the drug conjugate is to target gpNMB, also known as osteoactivan, which is important for cell migration and invasion. Vahdat says the hope among oncologists for glembatumumab vedotin is that the treatment can deliver a much higher dose of drug to the tumor than you normally would be able to, and directly into the tumor cell.
